Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Jun 22;2016(6):CD001909.
doi: 10.1002/14651858.CD001909.pub2.

Lamotrigine add-on for drug-resistant partial epilepsy

Sridharan Ramaratnam  1 , Mariangela Panebianco, Anthony G Marson
Affiliations
Meta-Analysis

Lamotrigine add-on for drug-resistant partial epilepsy

Sridharan Ramaratnam et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: This is an updated version of the Cochrane review published in The Cochrane Library 2010, Issue 1.Epilepsy is a common neurological disorder, affecting almost 0.5% to 1% of the population. For nearly 30% of these people, their epilepsy is refractory to currently available drugs. Pharmacological treatment remains the first choice to control epilepsy. Lamotrigine is one of the newer antiepileptic drugs and is the topic of this review. Lamotrigine in combination with other antiepileptic drugs (add-on) can reduce seizures, but with some adverse effects. The aim of this systematic review was to overview the current evidence for the efficacy and tolerability of lamotrigine when used as an adjunctive treatment for people with refractory partial epilepsy.

Objectives: To determine the effects of lamotrigine on (1) seizures, (2) adverse effect profile, and (3) cognition and quality of life, compared to placebo controls, when used as an add-on treatment for people with refractory partial epilepsy.

Search methods: For the previous version of the review, the authors searched the Cochrane Epilepsy Group Specialized Register (January 2010), the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library 2010, Issue 1), MEDLINE (1950 to January 2010), and reference lists of articles.For this update, we searched the Cochrane Epilepsy Group Specialized Register (28 May 2015), CENTRAL (The Cochrane Library 2015, Issue 4), MEDLINE (Ovid, 1946 to May 2015), and reference lists of articles. We also contacted the manufacturers of lamotrigine (GlaxoSmithKline). No language restrictions were imposed.

Selection criteria: Randomised placebo-controlled trials of people with drug-resistant partial epilepsy of any age, in which an adequate method of concealment of randomisation was used. The studies were double-, single- or unblinded. For cross-over studies, the first treatment period was treated as a parallel trial. Eligible participants were adults or children with drug-resistant partial epilepsy.

Data collection and analysis: For this update, two review authors independently assessed the trials for inclusion, and extracted data. Outcomes included 50% or greater reduction in seizure frequency, treatment withdrawal (any reason), adverse effects, effects on cognition and quality of life. Primary analyses were by intention-to-treat. Sensitivity best and worse case analyses were undertaken to account for missing outcome data. Pooled Risk Ratios (RR) with 95% confidence intervals (95% Cl) were estimated for the primary outcomes of seizure frequency and treatment withdrawal. For adverse effects, pooled RRs and 99% Cls were calculated.

Main results: We did not identify any new studies for this update, therefore, the results are unchanged.For the previous version of the review, the authors found five parallel add-on studies and eight cross-over studies in adults or children with refractory focal epilepsy, and one parallel add-on study with a responder-enriched design in infants. In total, these 14 studies included 1958 participants (38 infants, 199 children, and 1721 adults). Baseline phases ranged from 4 to 12 weeks; treatment phases from 8 to 36 weeks. Overall, eleven studies (n = 1243 participants) were rated as having a low risk of bias, and three (n = 715 participants) had un unclear risk of bias due to lack of reported information around study design. Effective blinding of studies was reported in three studies (n = 504 participants). The overall risk ratio (RR) for 50% or greater reduction in seizure frequency was 1.80 (95% CI 1.45 to 2.23; 12 RCTs) for twelve studies (n = 1322 participants, adults and children) indicating that lamotrigine was significantly more effective than placebo in reducing seizure frequency. The overall RR for treatment withdrawal (for any reason) was 1.11 (95% CI 0.90 to 1.36; 14 RCTs) for fourteen studies (n = 1958 participants). The adverse events significantly associated with lamotrigine were: ataxia, dizziness, diplopia, and nausea. The RR of these adverse effects were as follows: ataxia 3.34 (99% Cl 2.01 to 5.55; 12 RCTs; n = 1524); dizziness 2.00 (99% Cl 1.51 to 2.64;13 RCTs; n = 1767); diplopia 3.79 (99% Cl 2.15 to 6.68; 3 RCTs; n = 943); nausea 1.81 (99% Cl 1.22 to 2.68; 12 RCTs; n = 1486). The limited data available precluded any conclusions about effects on cognition and quality of life. No important heterogeneity between studies was found for any of the outcomes. Overall, we assessed the evidence as high to moderate quality, due to incomplete data for some outcomes.

Authors' conclusions: Lamotrigine as an add-on treatment for partial seizures appears to be effective in reducing seizure frequency, and seems to be fairly well tolerated. However, the trials were of relatively short duration and provided no evidence for the long-term. Further trials are needed to assess the long-term effects of lamotrigine, and to compare it with other add-on drugs.Since we did not find any new studies, our conclusions remain unchanged.

PubMed Disclaimer

Conflict of interest statement

SR: none known.

MP: none known.

AGM: A consortium of pharmaceutical companies (GSK, EISAI, UCB Pharma) funded the National Audit of Seizure Management in Hospitals (NASH) through grants paid to University of Liverpool. Professor Tony Marson is Theme Leader for Managing Complex Needs at NIHR CLAHRC NWC.

Figures

1
1
Study flow diagram for update.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Efficacy of add‐on lamotrigine versus placebo ‐ 50% responders, Outcome 1 Intention‐to‐treat analysis.
1.2
1.2. Analysis
Comparison 1 Efficacy of add‐on lamotrigine versus placebo ‐ 50% responders, Outcome 2 Worst case scenario.
1.3
1.3. Analysis
Comparison 1 Efficacy of add‐on lamotrigine versus placebo ‐ 50% responders, Outcome 3 Best case scenario.
2.1
2.1. Analysis
Comparison 2 Treatment withdrawal (global outcome), Outcome 1 Withdrawal from treatment.
3.1
3.1. Analysis
Comparison 3 Adverse effects, Outcome 1 Ataxia.
3.2
3.2. Analysis
Comparison 3 Adverse effects, Outcome 2 Dizziness.
3.3
3.3. Analysis
Comparison 3 Adverse effects, Outcome 3 Fatigue.
3.4
3.4. Analysis
Comparison 3 Adverse effects, Outcome 4 Nausea.
3.5
3.5. Analysis
Comparison 3 Adverse effects, Outcome 5 Somnolence.
3.6
3.6. Analysis
Comparison 3 Adverse effects, Outcome 6 Diplopia.
3.7
3.7. Analysis
Comparison 3 Adverse effects, Outcome 7 Headache.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Baulac 2010 {published data only}
    1. Baulac M, Leon T, O'Brien TJ, Whalen E, Barrett J. A comparison of pregabalin, lamotrigine, and placebo as adjunctive therapy in patients with refractory partial‐onset seizures. Epilepsy Research 2010; Vol. 91, issue 1:10‐9. - PubMed
Binnie 1989 {published data only}
    1. Binnie CD, Debets RMC, Engelsman M, Meijer JWA, Meinardi H, Overweg J, et al. Double‐blind crossover trial of lamotrigine (Lamictal) as add‐on therapy in intractable epilepsy. Epilepsy Research 1989;4:222‐9. - PubMed
Boas 1996 {published and unpublished data}
    1. Boas J, Dam M, Friis ML, Kristensen O, Pedersen B, Gallagher J. Controlled trial of lamotrigine (Lamictal) for treatment‐resistant partial seizures. Acta Neurologica Scandinavica 1996;94:247‐52. - PubMed
Duchowny 1999 {published data only}
    1. Duchowny M, Pellock JM, Graf WD, Billard C, Gilman J, Casale E, et al. A placebo‐controlled trial of lamotrigine add‐on therapy for partial seizures in children. Neurology 1999;53(8):1724‐31. - PubMed
Jawad 1989 {published data only}
    1. Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (lamictal) for refractory partial seizures. Epilepsia 1989;30(3):356‐63. - PubMed
Loiseau 1990 {published data only}
    1. Loiseau P, Yuen AWC, Duche B, Menager T, Arne‐Bes MC. A randomised double‐blind placebo‐controlled crossover add‐on trial of lamotrigine in patients with treatment‐resistant partial seizures. Epilepsy Research 1990;7:136‐45. - PubMed
Matsuo 1993 {published data only}
    1. Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, et al. Placebo‐controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. US Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993;43:2284‐91. - PubMed
Messenheimer 1994 {published data only}
    1. Messenheimer J, Ramsay RE, Willmore LJ, Leroy RF, Zielinski JJ, Mattson R, et al. Lamotrigine therapy for partial seizures: A multicenter, placebo‐controlled, double‐blind, cross‐over trial. Epilepsia 1994;35(1):113‐21. - PubMed
Naritoku 2007 {published data only}
    1. Naritoku DK, Warnock CR, Messenheimer JA, Borgohain R, Evers S, Guekht AB, et al. Lamotrigine extended‐release as adjunctive therapy for partial seizures. Neurology 2007;69:1610‐8. - PubMed
Piña‐Garza 2008 {published data only}
    1. Piña‐Garza JE, Levisohn P, Gucuyener K, Mikati MA, Warnock CR, Conklin HS, et al. Adjunctive lamotrigine for partial seizures in patients aged 1 to 24 months. Neurology 2008;70:2099‐108. - PubMed
Schachter 1995 {published and unpublished data}
    1. Schachter SC, Leppik IE, Matsuo F, Messenheimer JA, Faught E, Moore EL, et al. Lamotrigine: a six‐month, placebo‐controlled, safety and tolerance study. Journal of Epilepsy 1995;8:201‐9.
Schapel 1993 {published and unpublished data}
    1. Schapel GJ, Beran RG, Vajda FJE, Berkovic SF, Mashford ML, Dunagan FM, et al. Double‐blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. Journal of Neurology, Neurosurgery, and Psychiatry 1993;56:448‐53. - PMC - PubMed
Schmidt 1993 {published and unpublished data}
    1. Schmidt D, Ried S, Rapp P. Add‐on treatment with lamotrigine for intractable partial epilepsy: a placebo‐controlled, cross‐over trial. Epilepsia 1993;34 Suppl(2):66.
Smith 1993 {published and unpublished data}
    1. Smith D, Baker GA, Davies G, Dewey M, Chadwick DW. Outcomes of add‐on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34(2):312‐22. - PubMed

References to studies excluded from this review

Biton 2010 {published data only}
    1. Biton V, Memmo J, Shukla R, Lee YY, Poverennova I, Demchenko V, et al. Adjunctive lamotrigine XR for primary generalized tonic‐clonic seizures in a randomized, placebo‐controlled study. Epilepsy & Behavior 2010; Vol. 19, issue 3:352‐8. - PubMed
Biton 2013 {published data only}
    1. Biton V, Shneker BF, Naritoku D, Hammer AE, Vuong A, Caldwell PT, et al. Long‐term tolerability and safety of lamotrigine extended‐release: pooled analysis of three clinical trials. Clinical Drug Investigation 2013;33(5):359‐64. - PubMed
Brzakovic 2012 {published data only}
    1. Brzakovic BB, Vezmar Kovacevic SD, Vucicevic KM, Miljkovic BR, Martinovic ZJ, Pokrajac MV, et al. Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics. Journal of Clinical Pharmacy & Therapeutics 2012;37(6):693‐7. - PubMed
Carignani 2004 {published data only}
    1. Carignani MAC, Matassa JCM. Controlled trial of lamotrigine for the treatment of refractory partial seizures. Epilepsia 2004;45 Suppl 3:135‐6.
Carignani 2006 {published data only}
    1. Carignani M, Matassa J, Rosso D. Controlled trial of lamotrigine for the treatment of refractory partial seizures. Epilepsia 2006;47 Suppl 3:124.
Cramer 2013 {published data only}
    1. Cramer JA, Sapin C, Francois C. Indirect comparison of clobazam and other therapies for Lennox‐Gastaut Syndrome. Acta Neurologica Scandinavica 2013;128(2):91‐9. - PubMed
French 2012 {published data only}
    1. French JA, Hammer AE, Vuong A, Messenheimer JA. Analysis of three lamotrigine extended‐release clinical trials: comparison of pragmatic ITT and LOCF methodologies. Epilepsy Research 2012;101(1‐2):141‐7. - PubMed
Girolineto 2012 {published data only}
    1. Girolineto BM, Alexandre Junior V, Sakamoto AC, Pereira LR. Interchangeability among therapeutic equivalents of lamotrigine: evaluation of quality of life. Brazilian Journal of Pharmaceutical Sciences 2012;48(1):95‐102.
Hammer 2008 {published data only}
    1. Hammer AE, Vuong A, Kustra R, Messenheimer JA. Pragmatic intent‐to‐treat analysis for lamotrigine extended release adjunctive therapy in patients with intractable partial seizures. Epilepsia 2008;49(Suppl 7):100.
Hartung 2012 {published data only}
    1. Hartung DM, Middleton L, Svoboda L, McGregor JC. Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort‐crossover study. CNS Drugs 2012;26(8):707‐16. - PMC - PubMed
Helmstaedter 2013 {published data only}
    1. Helmstaedter C, Witt J‐A. The longer‐term cognitive effects of adjunctive antiepileptic treatment with lacosamide in comparison with lamotrigine and topiramate in a naturalistic outpatient setting. Epilepsy & Behaviour 2013;26(2):182‐7. - PubMed
Kang 2012 {published data only}
    1. Kang HC, Hu Q, Liu XY, Xu F, Li X, Liu ZG, et al. Efficacy and safety of the combined therapy of valproic acid and lamotrigine for epileptics. Zhonghua yi xue za zhi 2012;92(17):1174‐8. - PubMed
Montouris 2007 {published data only}
    1. Montouris G, Alok A, Vuong A, VanLandingham K. An analysis of the efficacy of lamotrigine extended‐release adjunctive therapy in subjects with partial epilepsy by number of concomitant AEDs. Epilepsia 2007;48(Suppl 6):369.
Ohtahara 2007 {published data only}
    1. Ohtahara S, Iinuma K, Fujiwara T, Yamatogi Y. [Single‐blind and controlled comparative study of lamotrigine with zonisamide for refractory pediatric epilepsy]. Journal of the Japan Epilepsy Society 2007;25(4):425‐40.
Sander 1990 {published data only}
    1. Sander JWAS, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomised double‐blind placebo‐controlled add‐on trial of lamotrigine in patients with severe epilepsy. Epilepsy Research 1990;6:221‐6. - PubMed
Semah 2014 {published data only}
    1. Semah F, Thomas P, Coulbaut S, Derambure P. Early add‐on treatment vs alternative monotherapy in patients with partial epilepsy. Epileptic disorders 2014;16(2):165‐74. - PubMed
Stolarek 1994 {published data only}
    1. Stolarek I, Blacklaw J, Forrest G, Brodie MJ. Vigabatrin and lamotrigine in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry 1994;57:921‐4. - PMC - PubMed
Tomson 2012 {published data only}
    1. Tomson T, Hirsch L, Friedman D, Bester N, Hammer A, Irizarry M, et al. Evaluation of sudden unexpected death in epilepsy (SUDEP) occurring in lamotrigine (LTG) clinical trials. Epilepsia 2012;53(Suppl 5):118.
Tomson 2013 {published data only}
    1. Tomson T, Hirsch LJ, Friedman D, Bester N, Hammer A, Irizarry M, et al. Sudden unexpected death in epilepsy in lamotrigine randomized‐controlled trials. Epilepsia 2013;54(1):135‐40. - PubMed
Veendrick 2000 {published data only}
    1. Veendrick‐Meekes MJBM, Beun AM, Carpay JA, Arends LR, Schlosser A. Use of lamotrigine as adjunctive therapy in patients with mental retardation and epilepsy. An interim analysis of a double blind study with evaluation of behavioural effects. Epilepsia 2000;41(Suppl Florence):97.
Yamamoto 2012 {published data only}
    1. Yamamoto Y, Inoue Y, Matsuda K, Takahashi Y, Kagawa Y. Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients. Biological & Pharmaceutical Bulletin 2012;35(4):487‐93. - PubMed

Additional references

Banks 1991
    1. Banks GK, Beran RG. Neuropsychological assessment in lamotrigine treated epileptic patients. Clinical and Experimental Neurology 1991;28:230‐7. - PubMed
Barker‐Haliski 2014
    1. Barker‐Haliski M, Sills GJ, White HS. What are the arguments for and against rational therapy for epilepsy?. Advances in Experimental Medicine & Biology 2014;813:295‐308. - PubMed
Cockerell 1995
    1. Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results from the national general practice study of epilepsy. Lancet 1995;346:140‐4. - PubMed
Commission 1989
    1. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30(4):389‐99. - PubMed
Fisher 2005
    1. Fisher RS, Emde Boas W, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League A Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005;46(4):470‐2. - PubMed
GRADEpro 2014 [Computer program]
    1. McMaster University. GRADEpro. [Computer program on www.gradepro.org]. Version [insert date of use]. Hamilton, Canada: McMaster University, 2014.
Hauser 1993
    1. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935 ‐1984. Epilepsia 1993;34(3):453‐68. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Kirkham 2010
    1. Kirkham JJ, Dwan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:c365. [DOI: 10.1136/bmj.c365] - DOI - PubMed
Leach 1995
    1. Leach LJ, Lees G, Riddall DR. Lamotrigine. In: Levy RH, Mattson RH, Medlrum BS editor(s). Mechanisms of action in antiepileptic drugs. 4th Edition. New York: Raven Press, 1995.
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org/.
Loscher 2002
    1. Loscher W. Current status and future directions in the pharmacotherapy of epilepsy. Trends in Pharmacological Sciences 2002;23(3):113‐8. - PubMed
Lyer 2014
    1. Lyer A, Marson A. Pharmacotherapy of focal epilepsy. Expert Opinion on Pharmacotherapy 2014;15(11):1543‐51. - PubMed
Moore 2012
    1. Moore JL, Aggarwal P. Lamotrigine use in pregnancy. Expert Opinion on Pharmacotherapy 2012;13(8):1213‐6. - PubMed
Mula 2013
    1. Mula M. Emerging drugs for focal epilepsy. Expert Opinion on Emerging Drugs 2013;18(1):87‐95. - PubMed
Panebianco 2015
    1. Panebianco M, Rigby A, Weston J, Marson AG. Vagus nerve stimulation for partial seizures. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI: 10.1002/14651858.CD002896.pub2] - DOI - PMC - PubMed
RevMan 2014 [Computer program]
    1. 5.3. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Copenhagen: 5.3. The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Vajda 2013
    1. Vajda FJE, Dodd S, Horgan D. Lamotrigine in epilepsy, pregnancy and psychiatry ‐ a drug for all seasons?. Journal of Clinical Neuroscience 2013;20(1):13‐6. - PubMed
West 2015
    1. West S, Nolan SJ, Cotton J, Gandhi S, Weston J, Sudan A, et al. Surgery for epilepsy. Cochrane Database of Systematic Reviews 2015, Issue 7. [DOI: 10.1002/14651858.CD010541.pub2] - DOI - PubMed

References to other published versions of this review

Ramaratnam 2001
    1. Ramaratnam S, Marson AG, Baker GA. Lamotrigine add‐on for drug‐resistant partial epilepsy. Cochrane Database of Systematic Reviews 2001, Issue 3. [DOI: 10.1002/14651858.CD001909] - DOI - PubMed

Publication types

LinkOut - more resources